Subject self assessment of improvement between treatment groups using the IBS Global Improvement Scale; comparison of safety and tolerability between treatment groups with respect to adverse events & laboratory abnormalities. 12 Weeks [clinicaltrials_resource:2913477308900c8636ae808b3312b5c3]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Subject self assessment of improvement between treatment groups using the IBS Global Improvement Scale; comparison of safety and tolerability between treatment groups with respect to adverse events & laboratory abnormalities. 12 Weeks [clinicaltrials_resource:2913477308900c8636ae808b3312b5c3]
Bio2RDF identifier
2913477308900c8636ae808b3312b5c3
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:2913477308900c8636ae808b3312b5c3
measure [clinicaltrials_vocabulary:measure]
Subject self assessment of imp ...... ts & laboratory abnormalities.
time frame [clinicaltrials_vocabulary:time-frame]
identifier
clinicaltrials_resource:2913477308900c8636ae808b3312b5c3
title
Subject self assessment of imp ...... ratory abnormalities. 12 Weeks
@en
type
label
Subject self assessment of imp ...... 3477308900c8636ae808b3312b5c3]
@en